{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T20:14:07Z","timestamp":1777493647756,"version":"3.51.4"},"reference-count":91,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2013,10,1]],"date-time":"2013-10-01T00:00:00Z","timestamp":1380585600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,10,1]],"date-time":"2013-10-01T00:00:00Z","timestamp":1380585600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Hematology"],"published-print":{"date-parts":[[2013,10]]},"DOI":"10.1053\/j.seminhematol.2013.09.006","type":"journal-article","created":{"date-parts":[[2013,10,3]],"date-time":"2013-10-03T12:19:47Z","timestamp":1380802787000},"page":"271-283","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Targeted Therapies in Hematology and Their Impact on Patient Care: Chronic and Acute Myeloid Leukemia"],"prefix":"10.1053","volume":"50","author":[{"given":"Elias","family":"Jabbour","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorge","family":"Cortes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Farhad","family":"Ravandi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan","family":"O\u2019Brien","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hagop","family":"Kantarjian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1053\/j.seminhematol.2013.09.006_bib1","doi-asserted-by":"crossref","first-page":"3123","DOI":"10.1002\/cncr.26679","article-title":"Estimations of the increasing prevalence and plateau prevalence of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy","volume":"118","author":"Huang","year":"2012","journal-title":"Cancer"},{"issue":"5405","key":"10.1053\/j.seminhematol.2013.09.006_bib2","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/243290a0","article-title":"Letter: a new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining","volume":"243","author":"Rowley","year":"1973","journal-title":"Nature"},{"issue":"6","key":"10.1053\/j.seminhematol.2013.09.006_bib3","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1182\/blood.V82.6.1838.1838","article-title":"Role of p21 RAS in p210 bcr-abl transformation of murine myeloid cells","volume":"82","author":"Mandanas","year":"1993","journal-title":"Blood"},{"issue":"11","key":"10.1053\/j.seminhematol.2013.09.006_bib4","first-page":"1111","article-title":"Factor independence of human myeloid leukemia cell lines is associated with increased phosphorylation of the proto-oncogene Raf-1","volume":"22","author":"Okuda","year":"1994","journal-title":"Exp Hematol"},{"issue":"25","key":"10.1053\/j.seminhematol.2013.09.006_bib5","doi-asserted-by":"crossref","first-page":"11746","DOI":"10.1073\/pnas.92.25.11746","article-title":"The Bcr-Abl leukemia oncogene activates Jun kinase and requires Jun for transformation","volume":"92","author":"Raitano","year":"1995","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"10.1053\/j.seminhematol.2013.09.006_bib6","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/0092-8674(92)90241-4","article-title":"Dominant negative MYC blocks transformation by ABL oncogenes","volume":"70","author":"Sawyers","year":"1992","journal-title":"Cell"},{"issue":"2","key":"10.1053\/j.seminhematol.2013.09.006_bib7","first-page":"247","article-title":"Constitutive activation of STAT5 by the BCR-ABL oncogene in chronic myelogenous leukemia","volume":"13","author":"Shuai","year":"1996","journal-title":"Oncogene"},{"issue":"3","key":"10.1053\/j.seminhematol.2013.09.006_bib8","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1084\/jem.183.3.811","article-title":"Tyrosyl phosphorylation and DNA binding activity of signal transducers and activators of transcription (STAT) proteins in hematopoietic cell lines transformed by Bcr\/Abl","volume":"183","author":"Carlesso","year":"1996","journal-title":"J Exp Med"},{"issue":"49","key":"10.1053\/j.seminhematol.2013.09.006_bib9","doi-asserted-by":"crossref","first-page":"31704","DOI":"10.1074\/jbc.271.49.31704","article-title":"P210 and P190 (BCR\/ABL) induce the tyrosine phosphorylation and DNA binding activity of multiple specific STAT family members","volume":"271","author":"Ilaria","year":"1996","journal-title":"J Biol Chem"},{"issue":"5","key":"10.1053\/j.seminhematol.2013.09.006_bib10","first-page":"1517","article-title":"An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: developed for the American Society of Hematology","volume":"94","author":"Silver","year":"1999","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2013.09.006_bib11","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V114.22.1126.1126","article-title":"International randomized study of interferon v STI571 (IRIS) 8-year follow up: sustained survival and low risk for progression of events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib","volume":"114","author":"Deininger","year":"2009","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2013.09.006_bib12","unstructured":"National Cancer Institute. SEER stat fact sheets: acute myeloid leukemia. 2012. Bethesda, MD. Accessed April 2013."},{"issue":"13","key":"10.1053\/j.seminhematol.2013.09.006_bib13","doi-asserted-by":"crossref","first-page":"4325","DOI":"10.1182\/blood-2002-03-0772","article-title":"Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461)","volume":"100","author":"Byrd","year":"2002","journal-title":"Blood"},{"issue":"12","key":"10.1053\/j.seminhematol.2013.09.006_bib14","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1056\/NEJMoa1112304","article-title":"Prognostic relevance of integrated genetic profiling in acute myeloid leukemia","volume":"366","author":"Patel","year":"2012","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1053\/j.seminhematol.2013.09.006_bib15","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1172\/JCI9083","article-title":"Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia","volume":"105","author":"Druker","year":"2000","journal-title":"J Clin Invest"},{"issue":"11","key":"10.1053\/j.seminhematol.2013.09.006_bib16","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","article-title":"Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia","volume":"348","author":"O'Brien","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminhematol.2013.09.006_bib17","doi-asserted-by":"crossref","first-page":"6658","DOI":"10.1021\/jm049486a","article-title":"Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src\/Abl kinase inhibitor with potent antitumor activity in preclinical assays","volume":"47","author":"Lombardo","year":"2004","journal-title":"J Med Chem"},{"issue":"11","key":"10.1053\/j.seminhematol.2013.09.006_bib18","doi-asserted-by":"crossref","first-page":"4500","DOI":"10.1158\/0008-5472.CAN-05-0259","article-title":"In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants","volume":"65","author":"O'Hare","year":"2005","journal-title":"Cancer Res"},{"issue":"11","key":"10.1053\/j.seminhematol.2013.09.006_bib19","doi-asserted-by":"crossref","first-page":"5790","DOI":"10.1158\/0008-5472.CAN-05-4187","article-title":"The structure of dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants","volume":"66","author":"Tokarski","year":"2006","journal-title":"Cancer Res"},{"issue":"5682","key":"10.1053\/j.seminhematol.2013.09.006_bib20","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1126\/science.1099480","article-title":"Overriding imatinib resistance with a novel ABL kinase inhibitor","volume":"305","author":"Shah","year":"2004","journal-title":"Science"},{"issue":"24","key":"10.1053\/j.seminhematol.2013.09.006_bib21","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","article-title":"Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia","volume":"362","author":"Kantarjian","year":"2010","journal-title":"N Engl J Med"},{"issue":"suppl","key":"10.1053\/j.seminhematol.2013.09.006_bib22","article-title":"Dasatinib versus imatinib (IM) in newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): DASISION 3-year follow-up","volume":"30","author":"Shah","year":"2012","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1053\/j.seminhematol.2013.09.006_bib23","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ccr.2005.01.007","article-title":"Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl","volume":"7","author":"Weisberg","year":"2005","journal-title":"Cancer Cell"},{"issue":"24","key":"10.1053\/j.seminhematol.2013.09.006_bib24","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","article-title":"Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia","volume":"362","author":"Saglio","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminhematol.2013.09.006_bib25","first-page":"1676","article-title":"Enestnd 4-year (y) update: continued superiority of nilotinib vs imatinib in patients (pts) with newly diagnosed Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia in chronic phase (CML-CP)","volume":"120","author":"Kantarjian","year":"2012","journal-title":"ASH Annual Meeting Abstracts"},{"issue":"14","key":"10.1053\/j.seminhematol.2013.09.006_bib26","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1200\/JCO.2009.26.3087","article-title":"Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib","volume":"28","author":"Marin","year":"2010","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1053\/j.seminhematol.2013.09.006_bib27","doi-asserted-by":"crossref","first-page":"481","DOI":"10.2165\/00019053-200725060-00004","article-title":"Treatment interruptions and non-adherence with imatinib and associated healthcare costs: a retrospective analysis among managed care patients with chronic myelogenous leukaemia","volume":"25","author":"Darkow","year":"2007","journal-title":"Pharmacoeconomics"},{"issue":"22","key":"10.1053\/j.seminhematol.2013.09.006_bib28","doi-asserted-by":"crossref","first-page":"5401","DOI":"10.1182\/blood-2008-12-196543","article-title":"Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study","volume":"113","author":"Noens","year":"2009","journal-title":"Blood"},{"issue":"10","key":"10.1053\/j.seminhematol.2013.09.006_bib29","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1182\/blood-2008-04-154344","article-title":"Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib therapy","volume":"113","author":"Jabbour","year":"2009","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2013.09.006_bib30","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1182\/blood.V118.21.3780.3780","article-title":"Impact of second-generation tyrosine kinase inhibitors as second line treatment for patients with chronic myeloid leukemia","volume":"118","author":"Garcia-Gutierrez","year":"2011","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2013.09.006_bib31","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1182\/blood.V118.21.2765.2765","article-title":"Efficacy of nilotinib versus high-dose imatinib in early chronic phase CML patients who have suboptimal molecular responses to standard-dose imatinib (RE-NICE multicenter study)","volume":"118","author":"Goh","year":"2011","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2013.09.006_bib32","doi-asserted-by":"crossref","first-page":"4136","DOI":"10.1002\/cncr.24504","article-title":"Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily: two-year follow-up of a randomized phase 2 study (START-R)","volume":"115","author":"Kantarjian","year":"2009","journal-title":"Cancer"},{"key":"10.1053\/j.seminhematol.2013.09.006_bib33","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1182\/blood.V118.21.451.451","article-title":"Upfront imatinib therapy in CML patients with rapid switching to nilotinib for failure to achieve molecular targets or intolerance achieves high overall rates of molecular response and a low risk of progression\u2014 an update of the TIDEL-II trial","volume":"118","author":"Yeung","year":"2011","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2013.09.006_bib34","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1002\/cncr.24325","article-title":"Dasatinib early intervention after cytogenetic or hematologic resistance to imatinib in patients with chronic myeloid leukemia","volume":"115","author":"Quintas-Cardama","year":"2009","journal-title":"Cancer"},{"issue":"5","key":"10.1053\/j.seminhematol.2013.09.006_bib35","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.ccr.2009.09.028","article-title":"AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance","volume":"16","author":"O'Hare","year":"2009","journal-title":"Cancer Cell"},{"key":"10.1053\/j.seminhematol.2013.09.006_bib36","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1056\/NEJMoa1205127","article-title":"Ponatinib in refractory Philadelphia chromosome-positive leukemias","volume":"367","author":"Cortes","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminhematol.2013.09.006_bib37","first-page":"163","volume":"120","author":"Cortes","year":"2012","journal-title":"ASH Annual Meeting Abstracts"},{"issue":"4","key":"10.1053\/j.seminhematol.2013.09.006_bib38","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/j.ccr.2011.03.003","article-title":"Conformational control inhibition of the BCR-ABL1 tyrosine kinase, including the gatekeeper T315I mutant, by the switch-control inhibitor DCC-2036","volume":"19","author":"Chan","year":"2011","journal-title":"Cancer Cell"},{"issue":"23","key":"10.1053\/j.seminhematol.2013.09.006_bib39","doi-asserted-by":"crossref","first-page":"5382","DOI":"10.1002\/cncr.24601","article-title":"Homoharringtonine, omacetaxine mepesuccinate, and chronic myeloid leukemia circa 2009","volume":"115","author":"Quintas-Cardama","year":"2009","journal-title":"Cancer"},{"issue":"8","key":"10.1053\/j.seminhematol.2013.09.006_bib40","doi-asserted-by":"crossref","first-page":"4355","DOI":"10.1182\/blood-2007-09-113175","article-title":"Simultaneous targeting of Aurora kinases and Bcr-Abl kinase by the small molecule inhibitor PHA-739358 is effective against imatinib-resistant BCR-ABL mutations including T315I","volume":"111","author":"Gontarewicz","year":"2008","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2013.09.006_bib41","doi-asserted-by":"crossref","first-page":"6041","DOI":"10.1200\/JCO.2009.25.0779","article-title":"Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet","volume":"27","author":"Baccarani","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2013.09.006_bib42","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1182\/blood-2006-02-005686","article-title":"Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet","volume":"108","author":"Baccarani","year":"2006","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2013.09.006_bib43","unstructured":"O\u2019Brien SAC, Akhtari M, et al. NCCN clinical practice guidelines in oncology: chronic myelogenous leukemia. Available at NCCN.org. Version 2, 2013."},{"key":"10.1053\/j.seminhematol.2013.09.006_bib44","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1182\/blood-2006-01-0092","article-title":"Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results","volume":"108","author":"Hughes","year":"2006","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2013.09.006_bib45","doi-asserted-by":"crossref","first-page":"4497","DOI":"10.1182\/blood-2008-12-191254","article-title":"Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of high-risk, Philadelphia-positive chronic myeloid leukemia: a European LeukemiaNet Study","volume":"113","author":"Baccarani","year":"2009","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2013.09.006_bib46","unstructured":"NCCN: National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: chronic myelogenous leukemia. (NCCN Guidelines\u00ae). NCCN Version 4. 2013."},{"key":"10.1053\/j.seminhematol.2013.09.006_bib47","doi-asserted-by":"crossref","first-page":"4437","DOI":"10.1182\/blood-2008-06-162388","article-title":"European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor","volume":"112","author":"Marin","year":"2008","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2013.09.006_bib48","doi-asserted-by":"crossref","first-page":"3758","DOI":"10.1182\/blood-2010-03-273979","article-title":"Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS)","volume":"116","author":"Hughes","year":"2010","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2013.09.006_bib49","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1002\/cncr.23238","article-title":"Cytogenetic and molecular responses and outcome in chronic myelogenous leukemia. Need for new response definitions?","volume":"112","author":"Kantarjian","year":"2008","journal-title":"Cancer"},{"key":"10.1053\/j.seminhematol.2013.09.006_bib50","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1200\/JCO.2010.32.0598","article-title":"Tolerability-adapted imatinib 800 mg\/d versus 400 mg\/d versus 400 mg\/d plus interferon-\u03b1 in newly diagnosed chronic myeloid leukemia","volume":"29","author":"Hehlmann","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2013.09.006_bib51","doi-asserted-by":"crossref","first-page":"3358","DOI":"10.1200\/JCO.2007.15.8154","article-title":"Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis","volume":"26","author":"de Lavallade","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2013.09.006_bib52","doi-asserted-by":"crossref","first-page":"4541","DOI":"10.1182\/blood-2011-04-348110","article-title":"The achievement of an early complete cytogenetic response is a major determinant of outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors","volume":"118","author":"Jabbour","year":"2011","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2013.09.006_bib53","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1038\/leu.2012.85","article-title":"Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML)","volume":"26","author":"Hanfstein","year":"2012","journal-title":"Leukemia"},{"key":"10.1053\/j.seminhematol.2013.09.006_bib54","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V120.21.1675.1675","article-title":"Early response (molecular and cytogenetic) and long-term outcomes in newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): exploratory analysis of DASISION 3-year data","volume":"120","author":"Saglio","year":"2012","journal-title":"Blood"},{"issue":"suppl","key":"10.1053\/j.seminhematol.2013.09.006_bib55","volume":"120","author":"Hochhaus","year":"2012","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2013.09.006_bib56","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1200\/JCO.2011.38.6565","article-title":"Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors","volume":"30","author":"Marin","year":"2012","journal-title":"J Clin Oncol"},{"issue":"suppl","key":"10.1053\/j.seminhematol.2013.09.006_bib57","article-title":"Can the combination of the measurement of BCR-ABL1 transcript levels at 3 and 6 months improve the prognostic value of the 3 month measurement?","volume":"120","author":"Neelakantan","year":"2012","journal-title":"Blood"},{"issue":"24","key":"10.1053\/j.seminhematol.2013.09.006_bib58","doi-asserted-by":"crossref","first-page":"4867","DOI":"10.1182\/blood-2013-03-490128","article-title":"Early responses predicts for better outcomes in patients with newly diagnosed CML: results with four TKI modalities","volume":"121","author":"Jain","year":"2013","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2013.09.006_bib59","doi-asserted-by":"crossref","first-page":"3659","DOI":"10.1200\/JCO.2008.18.6999","article-title":"Significance of increasing levels of minimal residual disease in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in complete cytogenetic response","volume":"27","author":"Kantarjian","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2013.09.006_bib60","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","article-title":"Intergroupe Fran\u00e7ais des leuc\u00e9mies my\u00e9lo\u00efdes chroniques. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre stop imatinib (STIM) trial","volume":"11","author":"Mahon","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1053\/j.seminhematol.2013.09.006_bib61","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V118.21.603.603","article-title":"Discontinuation of imatinib in patients with chronic myeloid leukemia who have maintained complete molecular response: update results of the STIM study","volume":"118","author":"Mahon","year":"2011","journal-title":"Blood"},{"issue":"2","key":"10.1053\/j.seminhematol.2013.09.006_bib62","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1097\/MOH.0b013e3283439a03","article-title":"FLT3 inhibitors: a story of the old and the new","volume":"18","author":"Fathi","year":"2011","journal-title":"Curr Opin Hematol"},{"key":"10.1053\/j.seminhematol.2013.09.006_bib63","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1182\/blood-2008-02-140392","article-title":"Conflicting data on the prognostic significance of FLT3\/TKD mutations in acute myeloid leukemia might be related to the incidence of biallelic disease","volume":"112","author":"Mead","year":"2008","journal-title":"Blood"},{"issue":"9","key":"10.1053\/j.seminhematol.2013.09.006_bib64","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1016\/j.bbmt.2011.02.003","article-title":"Role of allogeneic transplantation for FLT3\/ITD acute myeloid leukemia: outcomes from 133 newly diagnosed patients from a single institution","volume":"17","author":"DeZern","year":"2001","journal-title":"Biol Blood Marrow Transplant"},{"issue":"7397","key":"10.1053\/j.seminhematol.2013.09.006_bib65","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1038\/nature11016","article-title":"Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia","volume":"485","author":"Smith","year":"2012","journal-title":"Nature"},{"issue":"12","key":"10.1053\/j.seminhematol.2013.09.006_bib66","doi-asserted-by":"crossref","first-page":"3294","DOI":"10.1182\/blood-2010-08-301796","article-title":"Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse","volume":"117","author":"Levis","year":"2011","journal-title":"Blood"},{"issue":"12","key":"10.1053\/j.seminhematol.2013.09.006_bib67","doi-asserted-by":"crossref","first-page":"3286","DOI":"10.1182\/blood-2010-01-266742","article-title":"FLT3 ligand impedes the efficacy of FLT3 inhibitors in vitro and in vivo","volume":"117","author":"Sato","year":"2011","journal-title":"Blood"},{"issue":"28","key":"10.1053\/j.seminhematol.2013.09.006_bib68","doi-asserted-by":"crossref","first-page":"4339","DOI":"10.1200\/JCO.2010.28.9678","article-title":"Phase IIB trial of oral midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3","volume":"28","author":"Fischer","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2013.09.006_bib69","unstructured":"Nexavar (sorafenib) package insert. Wayne, NJ. Bayer Healthcare Pharmaceuticals, Inc. 12\/2012."},{"issue":"1","key":"10.1053\/j.seminhematol.2013.09.006_bib70","doi-asserted-by":"crossref","first-page":"62","DOI":"10.3324\/haematol.2010.030452","article-title":"Phase I study of sorafenib in patients with refractory or relapsed acute leukemias","volume":"96","author":"Borthakur","year":"2011","journal-title":"Haematologica"},{"issue":"26","key":"10.1053\/j.seminhematol.2013.09.006_bib71","doi-asserted-by":"crossref","first-page":"6567","DOI":"10.1182\/blood-2009-03-208298","article-title":"Compassionate use of sorafenib in FLT3-ITD-positive acute myeloid leukemia: sustained regression before and after allogeneic stem cell transplantation","volume":"113","author":"Metzelder","year":"2009","journal-title":"Blood"},{"issue":"23","key":"10.1053\/j.seminhematol.2013.09.006_bib72","doi-asserted-by":"crossref","first-page":"4655","DOI":"10.1182\/blood-2013-01-480228","article-title":"Phase II study of azacitidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation","volume":"121","author":"Ravandi","year":"2013","journal-title":"Blood"},{"issue":"14","key":"10.1053\/j.seminhematol.2013.09.006_bib73","doi-asserted-by":"crossref","first-page":"2984","DOI":"10.1182\/blood-2009-05-222034","article-title":"AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia","volume":"114","author":"Zarrinkar","year":"2009","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2013.09.006_bib74","article-title":"Final results of a phase 2 open-label monotherapy efficacy and safety study of quizartinib (AC220) in patients > 60 years of age with FLT3 ITD positive or negative relapsed\/refractory acute myeloid leukemia","volume":"120","author":"Cortes","year":"2012","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"10.1053\/j.seminhematol.2013.09.006_bib75","volume":"120","author":"Levis","year":"2012","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"9","key":"10.1053\/j.seminhematol.2013.09.006_bib76","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1002\/cncr.25717","article-title":"Practical advice for determining the role of BCR-ABL mutations in guiding tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia","volume":"117","author":"Jabbour","year":"2011","journal-title":"Cancer"},{"key":"10.1053\/j.seminhematol.2013.09.006_bib77","article-title":"Crenolanib (CP-868,596) is a potent and selective type I FLT3 inhibitor that retains activity against AC220 resistance-causing FLT3 kinase domain mutations","volume":"120","author":"Smith","year":"2012","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"24","key":"10.1053\/j.seminhematol.2013.09.006_bib78","doi-asserted-by":"crossref","first-page":"4854","DOI":"10.1182\/blood-2013-01-466706","article-title":"A phase III study of gemtuzumab ozogamicin during induction and post-consolidation therapy in younger patients with acute myeloid leukemia","volume":"121","author":"Petersdorf","year":"2013","journal-title":"Blood"},{"issue":"32","key":"10.1053\/j.seminhematol.2013.09.006_bib79","doi-asserted-by":"crossref","first-page":"3921","DOI":"10.1200\/JCO.2012.43.0132","article-title":"Gemtuzumab ozogamicin: time to resurrect?","volume":"30","author":"Ravandi","year":"2012","journal-title":"J Clin Oncol"},{"issue":"9825","key":"10.1053\/j.seminhematol.2013.09.006_bib80","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1016\/S0140-6736(12)60485-1","article-title":"Effect of gemtuzumab ozogamicin on survival of adult patients with de novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study","volume":"379","author":"Castaigne","year":"2012","journal-title":"Lancet"},{"issue":"4","key":"10.1053\/j.seminhematol.2013.09.006_bib81","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1200\/JCO.2010.31.4310","article-title":"Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC 15 trial","volume":"29","author":"Burnett","year":"2011","journal-title":"J Clin Oncol"},{"issue":"32","key":"10.1053\/j.seminhematol.2013.09.006_bib82","doi-asserted-by":"crossref","first-page":"3924","DOI":"10.1200\/JCO.2012.42.2964","article-title":"Addition of gemtuzumab ozogamicin to induction chemotherapy improves survival in older patients with acute myeloid leukemia","volume":"30","author":"Burnett","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2013.09.006_bib83","doi-asserted-by":"crossref","first-page":"4222","DOI":"10.1182\/blood-2001-12-0174","article-title":"Experience with gemtuzumab ozogamycin (\u201cMylotarg\u201d) and all-trans retinoic acid in untreated acute promyelocytic leukemia","volume":"99","author":"Estey","year":"2002","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2013.09.006_bib84","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1200\/JCO.2008.18.6130","article-title":"Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin","volume":"27","author":"Ravandi","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2013.09.006_bib85","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1182\/blood-2004-04-1550","article-title":"Gemtuzumab ozogamicin (Mylotarg) as a single agent for molecularly relapsed acute promyelocytic leukemia","volume":"104","author":"Lo-Coco","year":"2004","journal-title":"Blood"},{"issue":"9825","key":"10.1053\/j.seminhematol.2013.09.006_bib86","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1016\/S0140-6736(12)60534-0","article-title":"Treatment of AML: resurrection for gemtuzumab ozogamicin?","volume":"379","author":"Estey","year":"2012","journal-title":"Lancet"},{"issue":"1","key":"10.1053\/j.seminhematol.2013.09.006_bib87","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s11899-011-0103-0","article-title":"What happened to anti-CD33 therapy for acute myeloid leukemia?","volume":"7","author":"Jurcic","year":"2012","journal-title":"Curr Hematol Malig Rep"},{"issue":"18","key":"10.1053\/j.seminhematol.2013.09.006_bib88","doi-asserted-by":"crossref","first-page":"4110","DOI":"10.1200\/JCO.2005.09.133","article-title":"Phase III randomized multicenter study of a humanized anti-CD33 monoclonal antibody, lintuzumab, in combination with chemotherapy, versus chemotherapy alone in patients with refractory or first-relapsed acute myeloid leukemia","volume":"23","author":"Feldman","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2013.09.006_bib89","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V118.21.3613.3613","article-title":"Lintuzumab and low-dose cytarabine compared to placebo and low-dose cytarabine in patients with untreated acute myeloid leukemia 60 years and older: results of a randomized, double-blind phase 2b study","volume":"118","author":"lancet","year":"2011","journal-title":"Blood"},{"issue":"21","key":"10.1053\/j.seminhematol.2013.09.006_bib90","doi-asserted-by":"crossref","first-page":"5303","DOI":"10.1158\/1078-0432.CCR-10-0382","article-title":"Sequential cytarabine and alpha-particle immunotherapy with bismuth-213-lintuzumab (HuM195) for acute myeloid leukemia","volume":"16","author":"Rosenblat","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.seminhematol.2013.09.006_bib91","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V120.21.3625.3625","article-title":"SL-401, a targeted therapy directed to the interleukin-3 receptor present on leukemia blasts and cancer stem cells, is active as a single agent in patients with advanced AML","volume":"120","author":"Konopleva","year":"2012","journal-title":"Blood"}],"container-title":["Seminars in Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S003719631300125X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S003719631300125X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T06:22:18Z","timestamp":1758522138000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S003719631300125X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10]]},"references-count":91,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013,10]]}},"alternative-id":["S003719631300125X"],"URL":"https:\/\/doi.org\/10.1053\/j.seminhematol.2013.09.006","relation":{},"ISSN":["0037-1963"],"issn-type":[{"value":"0037-1963","type":"print"}],"subject":[],"published":{"date-parts":[[2013,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeted Therapies in Hematology and Their Impact on Patient Care: Chronic and Acute Myeloid Leukemia","name":"articletitle","label":"Article Title"},{"value":"Seminars in Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.seminhematol.2013.09.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}